Compare Eli Lilly And Co (LLY) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Stitch Fix Inc — how do they compare? Eli Lilly And Co trades at $1,173.98 (market cap $1.04T), while Stitch Fix Inc trades at $2.83 (market cap $366.07M). The key difference: Eli Lilly And Co is far larger — about 2841× Stitch Fix Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Stitch Fix Inc for 31 Days on average.
| LLY | SFIX | |
|---|---|---|
Market Cap | $1.04T | $366.07M |
Volume | 3,064,878 | 5,152,008 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $5.64 |
52-Week Low | $799.57 | $2.16 |
Typical Hold Time | 93 Days | 31 Days |
Enterprise Value | $1.09T | $261.88M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Stitch Fix (SFIX) trades at $2.775, up 1.65% on the day, but faces a bearish technical outlook with recent earnings beats overshadowed by weak forward guidance. The company reported a net loss of $28.74 million for 2025, though losses have narrowed significantly from prior years. Revenue remains stable at $1.27 billion, but negative cash flow and multiple law firm investigations into potential fraud create headwinds.
The investment outlook is cautious. While valuation appears cheap on a P/S basis and AI initiatives show promise, declining active clients, negative profitability metrics, and bearish analyst sentiment limit upside. The primary risk is execution against a challenging consumer backdrop, with the stock's trajectory hinging on a sustainable turnaround in client growth and margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
